SHAPE-enabled fragment-based ligand discovery for RNA

被引:25
|
作者
Zeller, Meredith J. [1 ]
Favorov, Oleg [2 ]
Li, Kelin [3 ]
Nuthanakanti, Ashok [4 ]
Hussein, Dina [5 ]
Michaud, Aureliane [5 ]
Lafontaine, Daniel A. [5 ]
Busan, Steven [1 ]
Serganov, Alexander [4 ]
Aube, Jeffrey [1 ,3 ]
Weeks, Kevin M. [1 ]
机构
[1] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Chapel Hill, NC 27599 USA
[4] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA
[5] Univ Sherbrooke, Fac Sci, Dept Biol, RNA Grp, Sherbrooke, PQ J1K 2R1, Canada
基金
加拿大健康研究院;
关键词
RNA-targeted ligand discovery; SHAPE-MaP; cooperativity; fragment linking; SELECTIVE 2'-HYDROXYL ACYLATION; PRIMER EXTENSION; STRUCTURAL BASIS; DRUG DISCOVERY; NONCODING RNAS; BINDING; TRANSCRIPTION; RIBOSWITCHES; INHIBITORS; MAP;
D O I
10.1073/pnas.2122660119
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The transcriptome represents an attractive but underused set of targets for smallmolecule ligands. Here, we devise a technology that leverages fragment-based screening and SHAPE-MaP RNA structure probing to discover small-molecule fragments that bind an RNA structure of interest. We identified fragments and cooperatively binding fragment pairs that bind to the thiamine pyrophosphate (TPP) riboswitch with millimolar to micromolar affinities. We then used structure-activity relationship information to efficiently design a linked-fragment ligand, with no resemblance to the native ligand, with high ligand efficiency and druglikeness, that binds to the TPP thiM riboswitch with high nanomolar affinity and that modulates RNA conformation during cotranscriptional folding. Principles from this work are broadly applicable, leveraging cooperativity and multisite binding, for developing high-quality ligands for diverse RNA targets.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Fragonomics: fragment-based drug discovery
    Zartler, ER
    Shapiro, MJ
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2005, 9 (04) : 366 - 370
  • [42] Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery
    Zauhar, Randy J.
    Gianti, Eleonora
    Welsh, William J.
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2013, 27 (12) : 1009 - 1036
  • [43] Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery
    Randy J. Zauhar
    Eleonora Gianti
    William J. Welsh
    Journal of Computer-Aided Molecular Design, 2013, 27 : 1009 - 1036
  • [44] What makes a good fragment in fragment-based drug discovery?
    Konteatis, Zenon
    EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (07) : 723 - 726
  • [45] Strategies and experiences in fragment-based drug discovery
    Hubbard, Roderick E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 510 - 510
  • [46] Fragment-based lead discovery grows up
    Monya Baker
    Nature Reviews Drug Discovery, 2013, 12 : 5 - 7
  • [47] A rule of three for fragment-based lead discovery?
    Congreve, M
    Carr, R
    Murray, C
    Jhoti, H
    DRUG DISCOVERY TODAY, 2003, 8 (19) : 876 - 877
  • [48] Fragment-based lead discovery: leads by design
    Carr, RAE
    Congreve, M
    Murray, CW
    Rees, DC
    DRUG DISCOVERY TODAY, 2005, 10 (14) : 987 - 992
  • [49] Fragment-based drug discovery: Less is more
    Heightman, Tom D.
    CANCER RESEARCH, 2014, 74 (19)
  • [50] Case studies in fragment-based lead discovery
    Congreve, MS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2763 - U2763